You are here:
Dear Doctor Letter (Rote-Hand-Brief) on BCR-ABL tyrosine kinase inhibitors: Risk of reactivation of hepatitis B
2016.04.08
Active substance: imatinib, dasatinib, nilotinib, bosutinib, ponatinib
The pharmaceutical companies concerned are circulating information on the risk of reactivation of hepatitis B after treatment with BCR-ABL tyrosine kinase inhibitors and the necessity of examining patients with regard to hepatitis B viral load prior to commencing treatment.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN